TSC1 and tuberous sclerosis: TSC1 or TSC2 inactivation causes an increase of GTP-bound Rheb, which is a regulator of the mechanistic Target of Rapamycin pathway (mTOR) activity, effectively leading to one of the key characteristics of the TSC disease: an upregulation of the mTOR pathway activity.